The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.
The effects of endurance exercise alone or in addition to treatment with glucagon-like- peptide receptor agonists on insulin secretory capacity, will be determined in patients with type 2 diabetes. Included patients will be randomized to either 12 weeks of endurance exercise training 3 times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of endurance exercise training 3 times a week. Insulin secretory capacity will be determined by hyperglycemic clamp method before and after.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
3 months of therapeutic treatment with semaglutide
Xlab, Center for Healthy Aging, Department of Biomedical Sciences, University of Copenhagen
Copenhagen, Denmark
RECRUITINGInsulin secretion
By hyperglycemic clamp
Time frame: Change from baseline insulin secretion after Exercise intervention(12 weeks).
Insulin secretion
By hyperglycemic clamp
Time frame: Change from baseline insulin secretion after 3 months of therapeutic semaglutide treatment
Insulin secretion
By hyperglycemic clamp
Time frame: Change from baseline insulin secretion after 3 months of combined exercise and therapeutic semaglutide treatment
Insulin secretion
By Oral glucose tolerance test
Time frame: Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment
insulin sensitivity
Derived from hyperglycemic clamp and HOMA-IR
Time frame: Before and after (2 days) Exercise intervention(12 weeks). Before and after 3 months of therapeutic semaglutide treatment
Changes in plasma bone markers
Changes in baseline CTX, PNIP, Osteocalcin and alkaline phosphatase
Time frame: Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment
Glucose homeostasis
Changes in HbA1c
Time frame: Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cardiorespiratory fitness
Changes in maximal oxygen uptake
Time frame: Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment
Body composition
By DXA
Time frame: Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment